PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaKRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersEmerging targeted therapies for melanoma treatment (review)Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerPhase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Stachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of Akt and ERK pathwaysRas Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.Embryonic Stem Cells Promoting Macrophage Survival and Function are Crucial for Teratoma DevelopmentMutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancerBRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaA systems-level interrogation identifies regulators of Drosophila blood cell number and survival.Drugging the undruggable RAS: Mission possible?Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionCIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.The impact of polyphenols on chondrocyte growth and survival: a preliminary reportA Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signallingColorectal cancer carcinogenesis: a review of mechanismsRationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentmiR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.Kisspeptin/KISS1R System in Breast CancerUpstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growthEffect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells.Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer.Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
P2860
Q21129230-A87050AB-98DB-4961-8872-A1561E64B8D1Q26751520-5A1B76E0-DF99-43A1-9CC6-F79B87F1D022Q26781362-7716C33C-29B6-46CD-A36A-5BF76C556971Q26829997-EB6A7808-C9D9-40E5-8892-D8096E5CF775Q27315948-18A70374-41AF-4C15-90FD-84BCB70E3843Q27853084-27DC44D7-D60A-4656-9FD3-5E84B6E35172Q27853104-FB508E65-8513-4810-B8E5-689D910AA78AQ28079596-29595F4E-89EB-4D49-986B-B03411E87B89Q28260541-47A41207-8A51-4A35-A3F4-D5D1D9695929Q33623156-B3339C11-E13E-4DE4-A6D1-26D9E0543372Q33646519-60BDD6C1-B0A8-4AF5-8DA2-3EC40028B0ABQ33687272-3F909BC9-5F88-460F-87DE-765491CC969DQ33847075-D418ACF8-723B-4AAA-B349-285526CCFCD2Q34365949-74C031E1-0205-4C1E-911B-27281741C009Q34592684-F4582236-E2C8-4103-88BF-0732D2ACB7EAQ34615593-A023C8D9-5DF9-4A4A-8136-80D9BC3CE57BQ34667825-6ECBE9C6-C0C0-4BAF-8262-F9B289713359Q34786402-CBA5AEEF-E5C5-4C3E-8CC3-ECEB17FD05C1Q35154724-51B2A7FF-BC85-46F6-9A3C-6E23D3287807Q35163434-D5858B3A-60C3-47AA-9D76-C81B6E079914Q35530332-F270CF2C-E3E0-4A9C-BB66-5F4FFF6D6E4FQ35657827-49C8C5EB-C759-4050-87AA-625DBCC86965Q35677661-D22F00B8-7ED9-4944-A3C8-7AD4D3194829Q35767389-E0BAD8D1-CCF4-4F56-8CC9-A7CA5A4E210FQ35892362-C13F367B-B2E4-4FCF-B7C4-D5E8D9958A1BQ36105608-825B067D-576E-4801-B67A-7A5D5BB6F70FQ36127934-6A969C4A-7F29-4EBE-8892-FF9F042D2D1BQ36437111-FC1A9C92-223E-4691-9EA6-5B5BF885B15BQ36544152-98ADC9EC-FC40-4400-B564-1ADEA17B8E40Q36546319-E7674B16-515C-4DC3-BBB0-8EDFF58BF06EQ36814884-2BC5CED0-9C03-4780-84E3-22F479D2C070Q36849645-541ADC7E-4E84-4444-9627-6658A5D732E9Q36997524-2BE94D15-92CD-48EC-A392-001818E4E4F0Q37236236-EB34AA8A-F45E-4138-BEC6-2B21A3C591A5Q37249506-6C44D4DC-C842-4C12-A8DA-D9AEBA2B3765Q37254508-193A3937-F2AF-49B3-9641-A51D26910EEEQ37273093-308206AA-0B97-4DD8-A7E1-439508BF7A77Q37288375-4569A2AA-EB6E-421C-9DED-0FC9A2B1A810Q37301776-14885FEC-C470-44FE-B1E6-D428D084F843Q37301884-F8E9B4FE-890F-4705-B0B0-11776F569E3C
P2860
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
@en
type
label
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
@en
prefLabel
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
@en
P2860
P1476
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
@en
P2093
Carolyn D Britten
P2860
P2888
P304
P356
10.1007/S00280-013-2121-1
P577
2013-02-27T00:00:00Z
P6179
1046374838